Generex Biotechnology Corporation
GNBT · OTC
4/30/2021 | 1/31/2021 | 10/31/2020 | 7/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | -100% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -218.9% | – | 73.6% | 71.9% |
| R&D Expenses | $1 | $2 | $1 | $1 |
| G&A Expenses | $5 | $7 | $13 | $5 |
| SG&A Expenses | $5 | $7 | $13 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $6 | $8 | $14 | $5 |
| Operating Income | -$6 | -$9 | -$14 | -$5 |
| % Margin | -30,746.6% | – | -15,958.6% | -900.6% |
| Other Income/Exp. Net | $31 | -$16 | $3 | -$7 |
| Pre-Tax Income | $25 | -$0 | -$0 | -$12 |
| Tax Expense | $16 | -$15 | $4 | -$5 |
| Net Income | $9 | -$0 | -$0 | -$13 |
| % Margin | 44,566.3% | – | -291.7% | -2,153.8% |
| EPS | 0.081 | -0.22 | -0.11 | -0.15 |
| % Growth | 136.6% | -100% | 26.7% | – |
| EPS Diluted | 0.066 | -0.22 | -0.11 | -0.15 |
| Weighted Avg Shares Out | 115 | 110 | 97 | 77 |
| Weighted Avg Shares Out Dil | 140 | 110 | 97 | 77 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $1 | $1 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $10 | -$24 | -$10 | -$10 |
| % Margin | 47,438.5% | – | -10,959.1% | -1,697.2% |